Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04382911 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04382911 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 8 participants.
The verdict
NCT04382911, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Purpose: The primary objective is to evaluate the sensitivity and specificity of 18F-fluoroestradiol (FES) PET/MRI for evaluating endometriosis. Participants: A total of 12 participants will be recruited from individuals with clinically suspected endometriosis who are scheduled for planned operative laparoscopy at the University of North Carolina at Chapel Hill (UNC). Procedures (methods): This is a prospective, one arm, single center study of 12 subjects with clinically suspected endometriosis to demonstrate FES PET/MR's clinical utility for diagnosis of endometriosis. This study will be an evaluation of the radiotracer, FES, which binds to estrogen receptors and has previously been used to study estrogen receptor expression in tumors, to detect endometriosis. Participants will undergo one FES PET/MR scan within 4 weeks prior to their scheduled surgery. Participants will also complete questionnaires regarding their condition, pain, and quality of life.
Interventions
- DRUG 18F-fluoroestradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-08-07 |
| Est. Completion | 2022-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04382911
The ClinicalTrials.gov registry entry for NCT04382911 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-fluoroestradiol is the first listed.
NCT04382911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04382911 about?
NCT04382911 is a clinical study titled "Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI". Purpose: The primary objective is to evaluate the sensitivity and specificity of 18F-fluoroestradiol (FES) PET/MRI for evaluating endometriosis. Participants: A total of 12 participants will be recruited from individuals with clinically suspected endometriosis who are scheduled for planned operativ...
What is the current status of trial NCT04382911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-08-07. Estimated completion is 2022-07-11.
What interventions are being tested in trial NCT04382911?
The interventions under investigation include: 18F-fluoroestradiol (DRUG).
Who is sponsoring clinical trial NCT04382911?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.